News
Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
July 25, 2014 | Press ReleaseGalectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma
July 22, 2014 | Press ReleaseGalectin Therapeutics Added to Russell 2000 Index
July 9, 2014 | Press ReleaseHighlights
View a New York Times article highlighting Galectin Therapeutics’ role in the fight against fatty liver disease
June 16, 2014 | News ArticleView a video recording of the 2014 Annual Stockholder Meeting
May 21, 2014 | WebcastView a presentation from the 2014 Annual Stockholder Meeting
May 14, 2014 | PresentationView Galectin Therapeutics’ webcast discussing first cohort results of Phase 1 clinical trial of GR-MD-02 in NASH
April 1, 2014 | WebcastView a webcast featuring Galectin Therapeutics’ CEO presenting at 16th Annual BIO CEO & Investor Conference
February 10, 2014 | Webcast
Galectin Therapeutics, Inc.
NASDAQ: GALT
15.32+1.60 Stock price updates every 30 minutes.